Tumor Control and Cranial Nerve Outcomes After Adjuvant Radiosurgery for Low-Grade Skull Base Meningiomas

Andrew Faramand, Hideyuki Kano, Ajay Niranjan, Kyung-Jae Park, John C. Flickinger, L. Dade Lunsford

Research output: Contribution to journalArticle

Abstract

Objective: We evaluated the tumor control and cranial nerve (CN)outcomes after adjuvant stereotactic radiosurgery (SRS)for petroclival, cavernous sinus, and cerebellopontine angle meningiomas. Methods: From our prospectively maintained database of 2022 patients with meningioma who had undergone Leksell SRS during a 30-year interval, we found 43 patients with petroclival, 94 with cavernous sinus, and 13 patients with cerebellopontine angle meningiomas who had undergone adjuvant SRS after surgical resection of the meningioma. The patients included in the present report had had ≥1 CN deficit at the initial presentation and a minimum follow-up period of 12 months. The median age at SRS was 54 years (range, 22–81). SRS was performed for residual tumor in 104 patients (69%)and recurrent tumor in 46 patients (31%). The median tumor volume treated with SRS was 8.1 cm 3 (range, 0.3–42), and the median margin dose was 13 Gy (range, 10–20). Results: Tumor control was achieved in 135 patients (90%)at a median follow-up point of 75 months. The progression-free survival rate after SRS was 99.5% at 1 year, 98% at 3 years, 95% at 5 years, and 90% at 10 years. Overall, 29 of the 150 patients (19%)reported improvement in CN function. Deterioration in CN function after SRS developed in 15 patients (10%). The rate of deterioration was 3.5% at 1 year, 5.5% at 3 years, and 7% at 5 years. Conclusions: Adjuvant SRS provides effective tumor control and a low rate of new or worsening CN deficits.

Original languageEnglish
JournalWorld Neurosurgery
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Radiosurgery
Cranial Nerves
Skull Base
Meningioma
Neoplasms
Cerebellopontine Angle
Cavernous Sinus
Residual Neoplasm
Tumor Burden
Disease-Free Survival
Survival Rate
Databases

Keywords

  • Cranial nerve
  • Meningioma
  • Radiation
  • Radiosurgery
  • Skull base

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Tumor Control and Cranial Nerve Outcomes After Adjuvant Radiosurgery for Low-Grade Skull Base Meningiomas. / Faramand, Andrew; Kano, Hideyuki; Niranjan, Ajay; Park, Kyung-Jae; Flickinger, John C.; Lunsford, L. Dade.

In: World Neurosurgery, 01.01.2019.

Research output: Contribution to journalArticle

Faramand, Andrew ; Kano, Hideyuki ; Niranjan, Ajay ; Park, Kyung-Jae ; Flickinger, John C. ; Lunsford, L. Dade. / Tumor Control and Cranial Nerve Outcomes After Adjuvant Radiosurgery for Low-Grade Skull Base Meningiomas. In: World Neurosurgery. 2019.
@article{29c6960cc09a42888acc3184f7b02e88,
title = "Tumor Control and Cranial Nerve Outcomes After Adjuvant Radiosurgery for Low-Grade Skull Base Meningiomas",
abstract = "Objective: We evaluated the tumor control and cranial nerve (CN)outcomes after adjuvant stereotactic radiosurgery (SRS)for petroclival, cavernous sinus, and cerebellopontine angle meningiomas. Methods: From our prospectively maintained database of 2022 patients with meningioma who had undergone Leksell SRS during a 30-year interval, we found 43 patients with petroclival, 94 with cavernous sinus, and 13 patients with cerebellopontine angle meningiomas who had undergone adjuvant SRS after surgical resection of the meningioma. The patients included in the present report had had ≥1 CN deficit at the initial presentation and a minimum follow-up period of 12 months. The median age at SRS was 54 years (range, 22–81). SRS was performed for residual tumor in 104 patients (69{\%})and recurrent tumor in 46 patients (31{\%}). The median tumor volume treated with SRS was 8.1 cm 3 (range, 0.3–42), and the median margin dose was 13 Gy (range, 10–20). Results: Tumor control was achieved in 135 patients (90{\%})at a median follow-up point of 75 months. The progression-free survival rate after SRS was 99.5{\%} at 1 year, 98{\%} at 3 years, 95{\%} at 5 years, and 90{\%} at 10 years. Overall, 29 of the 150 patients (19{\%})reported improvement in CN function. Deterioration in CN function after SRS developed in 15 patients (10{\%}). The rate of deterioration was 3.5{\%} at 1 year, 5.5{\%} at 3 years, and 7{\%} at 5 years. Conclusions: Adjuvant SRS provides effective tumor control and a low rate of new or worsening CN deficits.",
keywords = "Cranial nerve, Meningioma, Radiation, Radiosurgery, Skull base",
author = "Andrew Faramand and Hideyuki Kano and Ajay Niranjan and Kyung-Jae Park and Flickinger, {John C.} and Lunsford, {L. Dade}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.wneu.2019.03.052",
language = "English",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Tumor Control and Cranial Nerve Outcomes After Adjuvant Radiosurgery for Low-Grade Skull Base Meningiomas

AU - Faramand, Andrew

AU - Kano, Hideyuki

AU - Niranjan, Ajay

AU - Park, Kyung-Jae

AU - Flickinger, John C.

AU - Lunsford, L. Dade

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: We evaluated the tumor control and cranial nerve (CN)outcomes after adjuvant stereotactic radiosurgery (SRS)for petroclival, cavernous sinus, and cerebellopontine angle meningiomas. Methods: From our prospectively maintained database of 2022 patients with meningioma who had undergone Leksell SRS during a 30-year interval, we found 43 patients with petroclival, 94 with cavernous sinus, and 13 patients with cerebellopontine angle meningiomas who had undergone adjuvant SRS after surgical resection of the meningioma. The patients included in the present report had had ≥1 CN deficit at the initial presentation and a minimum follow-up period of 12 months. The median age at SRS was 54 years (range, 22–81). SRS was performed for residual tumor in 104 patients (69%)and recurrent tumor in 46 patients (31%). The median tumor volume treated with SRS was 8.1 cm 3 (range, 0.3–42), and the median margin dose was 13 Gy (range, 10–20). Results: Tumor control was achieved in 135 patients (90%)at a median follow-up point of 75 months. The progression-free survival rate after SRS was 99.5% at 1 year, 98% at 3 years, 95% at 5 years, and 90% at 10 years. Overall, 29 of the 150 patients (19%)reported improvement in CN function. Deterioration in CN function after SRS developed in 15 patients (10%). The rate of deterioration was 3.5% at 1 year, 5.5% at 3 years, and 7% at 5 years. Conclusions: Adjuvant SRS provides effective tumor control and a low rate of new or worsening CN deficits.

AB - Objective: We evaluated the tumor control and cranial nerve (CN)outcomes after adjuvant stereotactic radiosurgery (SRS)for petroclival, cavernous sinus, and cerebellopontine angle meningiomas. Methods: From our prospectively maintained database of 2022 patients with meningioma who had undergone Leksell SRS during a 30-year interval, we found 43 patients with petroclival, 94 with cavernous sinus, and 13 patients with cerebellopontine angle meningiomas who had undergone adjuvant SRS after surgical resection of the meningioma. The patients included in the present report had had ≥1 CN deficit at the initial presentation and a minimum follow-up period of 12 months. The median age at SRS was 54 years (range, 22–81). SRS was performed for residual tumor in 104 patients (69%)and recurrent tumor in 46 patients (31%). The median tumor volume treated with SRS was 8.1 cm 3 (range, 0.3–42), and the median margin dose was 13 Gy (range, 10–20). Results: Tumor control was achieved in 135 patients (90%)at a median follow-up point of 75 months. The progression-free survival rate after SRS was 99.5% at 1 year, 98% at 3 years, 95% at 5 years, and 90% at 10 years. Overall, 29 of the 150 patients (19%)reported improvement in CN function. Deterioration in CN function after SRS developed in 15 patients (10%). The rate of deterioration was 3.5% at 1 year, 5.5% at 3 years, and 7% at 5 years. Conclusions: Adjuvant SRS provides effective tumor control and a low rate of new or worsening CN deficits.

KW - Cranial nerve

KW - Meningioma

KW - Radiation

KW - Radiosurgery

KW - Skull base

UR - http://www.scopus.com/inward/record.url?scp=85064685282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064685282&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2019.03.052

DO - 10.1016/j.wneu.2019.03.052

M3 - Article

C2 - 30880202

AN - SCOPUS:85064685282

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -